Moreover, after treatment with biological therapies, RA patients often exhibit a decrease in CD14+ CD16+ monocyte levels, suggesting that these therapies may help modulate immune responses by reducing the pro-inflammatory monocyte population38, 39. Here, CD14 is linked to rheumatoid arthritis.